OptimizeRx Reports Q2 Earnings Amid Strategic Shift Toward Higher-Margin AI Offerings
OptimizeRx (OPRX) reported second-quarter revenue of $20.5 million, a 30% year-over-year decline primarily due to reduced activity from one large pharmaceutical customer and the company's strategic shift away from lower-margin managed services. Despite this drop in top-line growth, adjusted EBITDA reached $4.9 million as cost management and favorable channel partner mix helped offset revenue declines. The firm reiterated its full-year guidance of $95–$100 million in revenue and $21–$25 million in adjusted EBITDA, citing strong performance from AI software offerings that grew 25% year over year. Management also highlighted a successful debt refinancing with Fifth Third Bank at SOFR plus 2.25%, as well as recent principal payments reducing outstanding debt to $19.7 million by June 30. OptimizeRx is focusing on higher-margin, recurring subscription models and has authorized up to $10 million in stock buybacks under a 10b5-1 plan if the share price continues to decline.
Tickers: $OPRX
Topics: ai_software debt ebitda guidance revenue